Continuous Ambulatory Peritoneal Dialysis in Systemic Amyloidosis and End-Stage Renal Disease

Browning, Michael; Banks, Richard; Harrison, Peter; Tribe, C. R.; Fraley, Clare T; Zachary, Gill; Mackenzie, Campbell

doi:10.1177/014107688407700306

Cited by 24 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Haemodialysis (Jones 1976), CAPD (Browning et al 1984) and transplantation (Jones 1976, Kuhlback et al 1979), have all been described in the treatment of end-stage renal amyloidosis, but never before in a single patient. Our case illustrates many of the problems encountered in the management of these cases.…”

Section: Discussionmentioning

confidence: 99%

Replacement Therapy in End-Stage Renal Amyloidosis

et al. 1985

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Replacement Therapy in End-Stage Renal Amyloidosis

et al. 1985

View full text Add to dashboard Cite

“…The prognosis is rather poor -the median survival is usually less than 18 months [1]. In both types of amyloidosis, primary and secondary, kidney involvement is typical and frequent [2,3,4]. It usually manifests by proteinuria, mainly of nephrotic range [2,5].…”

Section: Introductionmentioning

confidence: 99%

“…In both types of amyloidosis, primary and secondary, kidney involvement is typical and frequent [2,3,4]. It usually manifests by proteinuria, mainly of nephrotic range [2,5]. The standard treatment of amyloidosis, e.g.…”

Section: Introductionmentioning

confidence: 99%

“…Further renal transplant has even been postulated [4]. Amyloid deposition, prolonged proteinuria and performed treatment of amyloidosis can injury the kidney, and finally lead to endstage renal disease (ESRD) [2,4]. If ESRD occurs, patients can be treated with all standard types of renal replacement therapy (RRT): peritoneal dialysis (PD), haemodialysis (HD) or renal transplant.…”

Section: Introductionmentioning

confidence: 99%

“…Some authors suggest that better patients , survival in PD than in HD [6]. In most available reports, amyloidosis patients on PD the survival rate was satisfactory but not impressive [2,3,7]. The case is presented of a woman with primary amyloidosis successfully treated with PD for more than seven years (87 months).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Long-time survival of a female with primary amyloidosis treated by peritoneal dialysis

Grzebalska¹,

Sak²,

Prystupa³

et al. 2017

J Pre Clin Clin Res.

View full text Add to dashboard Cite

Grzebalska A M, Sak J, Prystupa A, Książek A. Long-time survival of a female with primary amyloidosis treated by peritoneal dialysis. J PreClin Clin Res. 2017; 11(1): 22-24. doi: 10.26444/jpccr/75444 Abstract Introduction. Amyloidosis, both primary and secondary, is a systemic disease characterized by extracellular deposition of fibrillar protein in vital organs, leading to their injury and even insufficiency. It results in a poor diagnosis, especially for patients with primary amyloidosis. Kidney involvement is typical and usually manifests by proteinuria, mainly nephrotic range, leading to end-stage renal disease (ESRD). Patients with ESRD need renal replacement therapy (RRT). Some data claim that better results and longer patient , survival are observed in peritoneal dialysed rather than in haemodialysed patients. Case report. The case is described of 19-year-old Caucasian woman with primary amyloidosis. Inherited primary amyloidosis with abnormal apolipoprotein A-I was established. The patient was successfully treated with peritoneal dialysis for 87 months. After this period, she was transferred for haemodialysis. Such a long survival time on peritoneal dialysis (PD) in a patient with primary amyloidosis has not been found. It is believed that the lowering of immunoglobulin levels in blood and normalization of total protein in serum effectively removed, through dialysate, the pathological polyclonal proteins. This effect probably also sustained cardio-circulatory sufficiency of the patient and significantly prolonged her survival. Conclusion. Peritoneal dialysis is an effective and recommended method of treatment in patients suffering from primary amyloidosis. Peritoneal dialysis should be the first choice therapy in ESRD patient; contrary to haemodialysis, peritoneal dialysis removes pathological proteins and allows the avoidance of intra-dialytic hypotension.

show abstract

The Cutaneous Amyloidoses

Breathnach¹

1985

Arch Dermatol

View full text Add to dashboard Cite

Continuous Ambulatory Peritoneal Dialysis in Systemic Amyloidosis and End-Stage Renal Disease

Abstract: Three patients with end-stage renal failure complicating systemic amyloidosis have been treated with continuous ambulatory peritoneal dialysis for periods of 10, 14 and 18 months respectively. In each case satisfactory control of uraemia and fluid balance has been achieved.

Cited by 24 publications

References 8 publications

Replacement Therapy in End-Stage Renal Amyloidosis

Replacement Therapy in End-Stage Renal Amyloidosis

Long-time survival of a female with primary amyloidosis treated by peritoneal dialysis

The Cutaneous Amyloidoses

Contact Info

Product

Resources

About